Selank 5 mg Dosage Chart and Protocol

Use one complete set of measured and sterile research supplies for each prepared Selank 5 mg nasal bottle.

• Selank 5 mg research vial: One vial per prepared bottle, with lot-specific identity, purity, and assay documentation. The supplier card below links to the existing Selank 5 mg product page.
• Sterile research vehicle: Single-use sterile 0.9% sodium chloride for the worked saline example, or another validated sterile nasal research vehicle.
• Sterile nasal actuator bottle: One 5 mL or 10 mL bottle intended for single-user research.
• Metered pump: A compatible actuator documented or verified at 0.10 mL per complete spray.
• Calibrated transfer tools: Sterile syringes or pipettes that can measure the initial 3.0 mL and the exact 5.0 mL or 10.0 mL final volume.
• Sterile transfer needle: Required when the peptide vial uses a rubber septum.
• Clean handling supplies: Alcohol preparation pads, clean gloves, and a disinfected work surface.
• Label and research log: Record the peptide amount, final volume, concentration, pump output, preparation date, priming sprays, and actuation count.
• Storage materials: Light-protective, temperature-controlled storage appropriate to the validated formulation.
• Sharps container: Use when transfer needles are part of the preparation workflow.

View Supplier

• Primary human research route: Intranasal drops or measured intranasal solution.
• 5 mL final volume: 1 mg/mL, 100 mcg per verified 0.10 mL spray, and 50 nominal sprays.
• 10 mL final volume: 0.5 mg/mL, 50 mcg per verified 0.10 mL spray, and 100 nominal sprays.
• Device check: Confirm the pump output and follow its priming instructions before using the calculation.
• Research context: Human studies used different amounts, durations, and manufactured drop formulations.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic, tuftsin-derived heptapeptide studied by the intranasal route in anxiety-spectrum populations and healthy-volunteer neuroimaging research^[1][2][3][4]. This strength-specific page keeps the complete 5 mg vial, measured final volume, pump output, and published research context explicit without treating a calculation as a clinical recommendation.

Quick reference for the intranasal Selank 5 mg calculation.

• Human research route: Intranasal drops or solution.
• Peptide amount: 5,000 mcg total in the vial.
• 5 mL option: 1,000 mcg/mL and 100 mcg per verified 0.10 mL spray.
• 10 mL option: 500 mcg/mL and 50 mcg per verified 0.10 mL spray.
• Final-volume rule: Bring the transferred solution to an exact measured final volume.

Mathematical equivalents for a verified 0.10 mL actuator.

• 300 mcg: 3 sprays at 5 mL or 6 sprays at 10 mL.
• 900 mcg: 9 sprays at 5 mL or 18 sprays at 10 mL.
• 2,700 mcg: 27 sprays at 5 mL or 54 sprays at 10 mL.
• Whole vial: 50 nominal sprays at 5 mL or 100 nominal sprays at 10 mL.
• Interpretation: Match each amount to its original study, dropper, and formulation context.

Storage depends on the complete formulation, container, and handling method.

• Registered 0.15% product: Protected from light, stored at no more than 10 degrees C, and not frozen.
• Opened registered product: Follow that finished product’s manufacturer instructions; its labeled conditions do not apply to a custom research preparation.
• Custom research preparation: Use formulation-specific stability and microbiological controls rather than transferring the finished-product shelf life.
• Labeling: Record preparation date, final volume, concentration, vehicle, and storage conditions.

Human Selank research has primarily used the intranasal route. The studies below show the reported amount, formulation, and research setting so visitors can compare the literature without treating different protocols as interchangeable.

The current manufacturer instruction describes a 0.15% nasal-drop product at 1.5 mg/mL, with two drops placed in each nasal passage three times daily for 14 days. Those drop counts belong to the registered bottle and finished formulation. They are not direct equivalents to a different metered pump.

Reference concentration: Mathematically, 5 mg brought to about 3.33 mL equals 1.5 mg/mL. A verified 0.10 mL actuation at that concentration contains 150 mcg. This is a concentration comparison, not a reproduction of the registered preserved drop product.

A 0.10 mL actuator is a common nasal pump configuration, but pump output is not universal. Pharmaceutical literature reports pump volumes from approximately 0.025 mL to 0.20 mL per spray^[6]. Use the manufacturer specification or a validated measurement for the exact device.

Core Formula

mcg per spray = (5,000 mcg / final volume in mL) x verified mL per spray

nominal sprays = final volume in mL / verified mL per spray

Actuator Checks Before Recording a Result

• Confirm the stated volume per full actuation for the specific pump.
• Follow the documented priming and repriming procedure.
• Record residual volume and tail-off near bottle exhaustion when estimating usable sprays.
• Keep pump orientation and actuation stroke consistent during the research procedure.

FDA nasal spray guidance treats pump delivery, priming, dose uniformity, and bottle exhaustion as product performance variables^[7].

A Selank dosage chart is only interpretable when the final volume and actual actuator output are known. Small device and measurement differences can materially change the amount delivered per spray.

• Use a measured final volume, not the bottle capacity mark alone.
• Verify that the actuator releases 0.10 mL per full stroke before applying the main table.
• Prime and reprime exactly as specified for the pump, then record those actuations.
• Keep the bottle upright and use a complete, consistent stroke for each recorded spray.
• Treat the theoretical 50 or 100 sprays as nominal counts because priming and residual hold-up consume part of the volume.
• A 5 mg vial contains 5,000 mcg total. Calculate the complete peptide requirement before modeling any multi-day published protocol.
• Use a validated laboratory handling and stability plan for any custom multidose preparation.

Selank is a seven-amino-acid peptide derived from tuftsin. The primary human literature summarized here studied intranasal Selank in adults with generalized anxiety disorder, neurasthenia, phobic-anxiety or somatoform disorders, and in healthy volunteers undergoing functional-connectivity imaging^[1][3][4]. These studies do not make every commercial vial, custom vehicle, or nasal pump equivalent.

The Pure Lab Peptides listing supplies the 5 mg vial image and product-provenance link used on this page; it is not the scientific basis for the public research schedule^[8].

The human evidence is small and heterogeneous. A 2008 comparative study enrolled 62 people with generalized anxiety disorder or neurasthenia and compared Selank with medazepam using psychometric and biochemical measures^[1]. A separate report examined rapid and gradual response patterns during a 14-day intranasal course and included a single-exposure pharmaco-EEG analysis^[2].

A 2014 comparative trial enrolled 60 people with phobic-anxiety or somatoform disorders and compared Selank with phenazepam, while a 2020 study evaluated acute changes in resting-state functional connectivity in 52 healthy volunteers^[3][4]. Population, formulation, device, amount, and endpoint differences limit direct comparisons.

Mechanistic research has explored GABA-related signaling, gene expression, enkephalin metabolism, and brain-network connectivity. Rat frontal-cortex experiments reported changes in genes involved in neurotransmission after Selank exposure, but those findings are preclinical and cannot establish a human dose-response relationship^[9]. A molecular review also described effects on GABA binding in experimental systems^[10].

These findings can explain why Selank is discussed alongside GABAergic compounds, but they do not validate an unsupervised Selank peptide dosage, prove long-term safety, or replace controlled human research.

• The 2008 comparative study reported similar anxiety-related effects for Selank and medazepam, with additional anti-asthenic and psychostimulant observations in the Selank group^[1].
• In the 2012 GAD report, 40% of participants were classified as rapid responders during days 1 to 3, while 60% showed a gradual response pattern through day 14^[2].
• The 2014 comparison reported anxiolytic and mild nootropic findings, but the study was small and does not establish a universal protocol^[3].
• The healthy-volunteer neuroimaging study examined a single intranasal exposure and functional connectivity rather than a repeated clinical course^[4].
• A 2021 clinical-pharmacology review characterized Selank as poorly studied and emphasized the need for more safety evaluation^[5].

Nasal delivery is a device-formulation system, not simply a bottle label. Pump output, priming, repriming, dose uniformity, bottle orientation, and tail-off near exhaustion can alter the delivered volume^[6][7]. That is why this Selank 5 mg page shows both concentration and verified mL per spray.

The core relationship remains: mcg per spray equals vial mass divided by measured final volume, multiplied by verified actuator volume. A pump that releases a different volume requires recalculation; the existing schedule itself does not change.

• Pump specification: Record the stated or measured mL per actuation.
• Priming status: Document first use, repriming, and any missed sprays.
• Actuation technique: Keep bottle orientation, stroke length, and stroke force consistent.
• Nasal condition: Record congestion, irritation, or other conditions that could affect deposition.
• Formulation details: Record the vehicle, final volume, concentration, container, and storage conditions.
• Actuation count: Track sprays from priming through final use to identify tail-off and residual volume.

1. Inspect the labeled concentration and confirm the actuator output before use.
2. Prime or reprime the pump according to the manufacturer instructions.
3. Keep the bottle in the specified orientation and use one complete, smooth stroke.
4. Record each actuation immediately, including priming sprays.
5. Wipe the nozzle with a clean material appropriate for the device and replace the cap.
6. Return the bottle to its documented storage condition after the research procedure.

What does a Selank 5 mg vial represent?

It represents 5,000 mcg of total peptide in the vial. It does not mean 5 mg per spray or per administration.

How is the amount per spray calculated?

Divide 5,000 mcg by the measured final volume to obtain mcg/mL, then multiply by the verified mL released per full actuation. The main chart uses a verified 0.10 mL spray.

Why are both 5 mL and 10 mL preparations shown?

They illustrate how final volume changes concentration and spray count while keeping the vial mass fixed. The 5 mL option is twice as concentrated as the 10 mL option.

Can the 5 mg and 10 mg Selank pages be used interchangeably?

No. They describe the same peptide family but different vial masses, concentrations, and strength-specific actuator calculations. Each page keeps its own math and search intent.

Does this Selank dosing chart include injection calculations or recommend a clinical dose?

No. It translates the existing published intranasal research schedule and fixed device assumptions into transparent concentration and actuator math. The page does not establish an injection or subcutaneous injection schedule and is not personalized medical guidance.

This Selank 5 mg dosage guide is an educational research reference. It does not provide medical advice, diagnose or treat any condition, or establish safety for human use. Selank is presented for laboratory and research discussion only and is not intended for human consumption.

• 1
  Zozulia et al. (2008) Human comparative study of intranasal Selank in adults with generalized anxiety disorder or neurasthenia.

  View Source
• 2
  Syunyakov et al. (2012) Report of rapid and gradual response patterns during intranasal Selank research and a single-exposure pharmaco-EEG analysis.

  View Source
• 3
  Medvedev et al. (2014) Comparative clinical study of Selank and phenazepam in 60 adults with anxiety-spectrum or somatoform disorders.

  View Source
• 4
  Panikratova et al. (2020) Functional-connectivity study of acute intranasal Selank exposure in 52 healthy volunteers.

  View Source
• 5
  Doyno and White (2021) Clinical-pharmacology review discussing Selank within the GABAergic evidence and safety landscape.

  View Source
• 6
  Trows et al. (2014) Review of analytical challenges and regulatory requirements for nasal drug products, including pump-output variables.

  View Source
• 7
  U.S. Food and Drug Administration CMC guidance for nasal spray products covering pump delivery, priming, dose uniformity, and product performance.

  View Source
• 8
  Pure Lab Peptides Selank 5 mg research product page and batch-documentation destination used for product provenance.

  View Source
• 9
  Volkova et al. (2016) Preclinical study of Selank-associated gene-expression changes involving GABAergic neurotransmission.

  View Source
• 10
  Kozlovskii et al. (2018) Experimental review of molecular mechanisms proposed for the heptapeptide Selank.

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-size variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.